Diagnosis and treatment of digestive cancer by means of monoclonal antibodies

1.制备抗恶性腹水中胰腺癌相关抗原的单抗。免疫组织化学研究表明，这些抗体具有较高的抗胰腺癌特异性。鉴定了抗胎儿胰腺的单抗FP-1、FP-2和FP-3。FP-1、FP-2和FP-3分别与导管细胞、腺泡细胞和胰岛细胞反应。FP-1识别的多肽与15/21的胰腺癌组织反应，FP-2和FP-3识别的碳水化合物，FP-3与8/13的Apudoma(甲状腺髓样癌、肠类癌和嗜铬细胞瘤)反应。2.用特异性抗CEA单抗建立了循环CEA-IC的酶免疫分析方法。从28名健康志愿者中，初步确定了8U/ml的上限。53%(10/19)的转移性或复发性结直肠癌患者CEA-IC升高，其中3例CEA正常值。CEA-IC的生物化学相对分子质量在44万以上。3.为了建立合适的粪便CEA检测体系，用于GI癌症患者的筛查，我们的研究还需要进一步的研究。4.制备人-人杂交瘤细胞株。目前正在对这些杂交瘤进行筛选和鉴定。对于肿瘤成像和靶向，我们现在正在开发高特斯拉系统的磁共振成像。

1:Monoclonal antibodies against pancreatic cancer associated antigen from malignant pancreatic ascites were prepared. These antibodies showed high specificities against pancreatic cancer by immunohistological study. Monoclonal antibodies against fetal pancreas (FP-1,FP-2 and FP-3) were characterized. FP-1 ,FP-2 and FP-3 reacted respectively with ductal cells,acinar cells and islet cells. FP-1 recognized peptide and reacted with 15/21 of pancreatic cancer tissues.FP-2 and FP-3 recogognized carbohydrate and FP-3 reacted with 8/13 of Apudomas(medullary thyroid carcinomas, intestinal carcinoids and pheochromocytomas).2:Using specific anti-CEA monoclonal antibody,an enzyme-immunoassay for circulating CEA-IC has been developed. From a group of 28 healthy volunteers,an upper limit of 8U/ml has been tentatively determined. An elevated CEA-IC was shown in 53%(10/19) of patients with metastatic or recurrent colo rectal cancer,3 of them were of normal value of CEA. CEA-IC had a molecular weight of 440,000 or more biochemically.3.To develop appropriate assay system of fecal CEA determinations for screening of GI cancer patients, further study would be thought to be necessary from our research. 4.Human-Human hybridomas were prepared. Screening and characterization of these hybridomas were now underway. For tumor imaging and targeting, we are now developing <^(19)F> -Magnetic Resonance Imaging with high tesla system.